Skip to main
MDAI

MDAI Stock Forecast & Price Target

MDAI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spectral AI is well-positioned in the growing field of AI-driven medical diagnostics and wound healing. With its cutting-edge DeepView System and recent FDA clearance, the company is poised for strong revenue growth in the coming years. Additionally, its recent funding from BARDA and plans for a miniaturized handheld version of DeepView demonstrate a commitment to innovation and expansion in the market. These factors, combined with the large and under-penetrated market opportunity for advanced wound care, lead to a positive outlook for Spectral AI's stock.

Bears say

Spectral AI is expected to recognize revenue in line with its FY26 guidance of $18.5M from its existing BARDA contract, but its limited operating history and potential competition in the AI medical diagnostic market could pose risks to its commercial success. While FDA clearance for its DeepView system is a significant milestone, risks to its rating and PT include delays to regulatory and clinical timelines and limited reimbursement. A discounted sales analysis forecasts revenue of $18.5M at 5.5x NTM EV/Sales, leading to a $4 PT.

MDAI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spectral AI Inc (MDAI) Forecast

Analysts have given MDAI a Strong Buy based on their latest research and market trends.

According to 1 analysts, MDAI has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spectral AI Inc (MDAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.